Rezafungin acetate - Generic Drug Details

What are the generic sources for rezafungin acetate and what is the scope of freedom to operate?

Rezafungin acetate is the generic ingredient in one branded drug marketed by Mundipharma and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rezafungin acetate has one hundred and three patent family members in twenty-seven countries.

One supplier is listed for this compound.

Summary for rezafungin acetate

International Patents:	103
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	14
Clinical Trials:	2
DailyMed Link:	rezafungin acetate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for rezafungin acetate

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for rezafungin acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mundipharma Research Limited	PHASE2
Mundipharma Research Limited	Phase 1

See all rezafungin acetate clinical trials

Pharmacology for rezafungin acetate

Drug Class

Echinocandin Antifungal

Anatomical Therapeutic Chemical (ATC) Classes for rezafungin acetate

J02AX	Other antimycotics for systemic use
J02A	ANTIMYCOTICS FOR SYSTEMIC USE
J02	ANTIMYCOTICS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for rezafungin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	11,712,459		Y
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	8,722,619		Y	Y
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	9,526,835		Y	Y

International Patents for rezafungin acetate

Country	Patent Number	Title	Estimated Expiration
Hungary	E063336
San Marino	T201700460
Canada	2867132	POSOLOGIES POUR COMPOSES DE LA CLASSE DES ECHINOCANDINES (DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS)

Supplementary Protection Certificates for rezafungin acetate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2680873	122024000037	Germany		PRODUCT NAME: REZAFUNGIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE REZAFUNGINACETAT; REGISTRATION NO/DATE: EU/1/23/1775 20231222
2680873	PA2024520	Lithuania		PRODUCT NAME: REZAFUNGINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, YPAC REZAFUNGINO ACETATAS; REGISTRATION NO/DATE: EU/1/23/1775 20231222
2680873	CA 2024 00025	Denmark		PRODUCT NAME: REZAFUNGIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER REZAFUNGINACETAT; REG. NO/DATE: EU/1/23/1775 20231222

Market Dynamics and Financial Trajectory for Rezafungin Acetate

Last updated: December 16, 2025

Executive Summary

Rezafungin acetate (formerly CD101) is a novel, once-weekly intravenous antifungal agent developed by Cidara Therapeutics. With its innovative pharmacokinetic profile and broad-spectrum activity against invasive fungal infections, rezafungin presents a significant opportunity in the antifungal market. This analysis explores the drug’s market environment, competitive landscape, regulatory status, revenue potential, and strategic factors shaping its financial trajectory.

---

What is Rezafungin Acetate?

Rezafungin acetate is a next-generation echinocandin designed for once-weekly administration. Its pharmacokinetics enable higher dosing flexibility, improved tissue penetration, and potentially better adherence compared to existing antifungals like caspofungin, micafungin, and anidulafungin.

Key Attributes

Attribute	Details
Mechanism	Inhibits fungal cell wall synthesis via β-glucan synthesis inhibition
Administration	Intravenous, once-weekly
Indications	Invasive candidiasis, candidemia, invasive aspergillosis
Development Stage	Phase 3 (as of 2022)
Unique Selling Points	Long half-life, enhanced stability, broad-spectrum activity

---

Market Landscape and Opportunity

Global Market Size and Growth

Year	Market Size (USD billion)	CAGR (2018–2025)	Key Drivers
2022	$4.2 billion	8.5%	Rising invasive fungal infections, expanding immunocompromised populations
2025	$6.3 billion	-	Increasing antifungal resistance, aging demographics

Source: MarketResearch.com, July 2022.

Key Markets and Segments

Region	Market Share (2022)	Growth Drivers
North America	45%	High prevalence of invasive fungal infections, rapid adoption of novel agents
Europe	25%	Aging population, rising clinical use of antifungals
Asia-Pacific	20%	Expanding healthcare infrastructure, increasing immunosuppression cases
Rest of World	10%	Variable market access, emerging antifungal needs

---

Competitive Landscape

Major Players and Products

Company	Leading Agents	Market Position	Distinct Advantages
Pfizer (Caspofungin)	Cancidas (Caspofungin)	Market leader	Extensive experience, established efficacy
Astellas (Micafungin)	Mycamine (Micafungin)	Strong regional presence	Good safety profile
Pfizer (Anidulafungin)	Eraxis (Anidulafungin)	Niche but stable	Long half-life, once daily
Cidara Therapeutics	Rezafungin (CD101)	Emerging, in late-stage trials	Once-weekly dosing, broad spectrum

Potential Competitive Advantages of Rezafungin

• Long Half-Life: ~80 hours, enabling once-weekly dosing.
• Enhanced Stability: Better safety profile with less infusion-related reactions.
• Broad Spectrum: Active against common pathogenic fungi, including resistant strains.
• Reduced Dosing Burden: Potentially improves adherence and reduces hospitalization duration.

Regulatory Status

• FDA: Breakthrough Therapy designation granted (Dec 2020).
• EMA: Orphan drug designation for invasive candidiasis.
• Regulatory Milestones: Phase 3 trials completed preliminary safety assessments; NDA submission anticipated in 2023.

---

Financial Trajectory: Revenue Drivers and Forecasts

Revenue Assumptions

Factor	Impact	Quantitative Estimate
Market Penetration	Percentage of target market captured	10%-30% within 5 years post-approval (2023–2028)
Pricing	Per-vial or treatment course price	Estimated at $3,000–$5,000 per treatment course
Treatment Volume	Number of patients treated annually	~100,000 invasive fungal infection cases globally annually by 2028
Pricing Premium	Compared to existing echinocandins	10–20% premium due to dosing convenience and safety profile

Projected Revenue Timeline

Year	Estimated Revenue (USD million)	Key Assumptions
2022	$0 (Pending approval)	Regulatory approval not yet granted
2023	$50–100	Initial launch, capturing early adopters
2024	$200–400	Increased adoption, expanded indications
2025	$500–800	Market penetration stabilizes
2026+	$1 billion+	Potential for global adoption, line extensions

Note: These estimates assume successful regulatory approval and positive payer coverage policies.

---

Regulatory and Policy Considerations

FDA and EMA Milestones

• FDA: Rezafungin received Breakthrough Therapy designation to expedite development.
• EMA: Fast-track designation supported the advancement through the approval process.
• Approval Timeline: Anticipated submission in late 2022 with potential approval in 2023.

Pricing, Reimbursement, and Access

• Pricing Strategy: Likely premium justified by dosing convenience and clinical benefits.
• Reimbursement Challenges: Negotiation with payers critical; favorable policies in favor of long-acting antifungals could accelerate uptake.
• Global Access: Gaps expected in emerging markets without established distribution channels.

---

Comparison with Existing Therapies

Parameter	Rezafungin	Caspofungin / Micafungin / Anidulafungin	Advantages / Disadvantages
Dosing Frequency	Once-weekly	Daily	Improved adherence, reduced hospital visits
Pharmacokinetics	Long half-life (~80 hrs)	12–24 hrs	Less frequent dosing, steady drug levels
Spectrum of Activity	Broad, includes resistant strains	Similar spectrum	Slightly enhanced activity spectrum
Safety Profile	Favorable, less infusion reactions	Established but with infusion reactions	Enhanced safety profile anticipated
Market Penetration	Pending approval	Mature	Higher adoption likelihood post-approval

---

Strategic Factors Influencing Financial Outcomes

Market Penetration Factors

• Early adoption by leading hospitals and infusion centers will be vital.
• Post-marketing studies demonstrating cost-effectiveness will support payer coverage.
• Clinician familiarity with once-weekly dosing could establish a competitive edge.

Pricing Strategies

• Premium pricing justified by dosing convenience and safety.
• Value-based pricing could be negotiated based on reduced hospital stays and improved compliance.

Pipeline and Line Extensions

• Development of oral formulations could expand market access.
• Combination therapies for resistant strains require exploration.

---

Key Challenges and Risks

Risk Factor	Potential Impact	Mitigation Strategies
Regulatory delays or failure to approve	Revenue postponement, financial shortfalls	Robust clinical data, continuous engagement with regulators
Competitive pressures from existing agents	Market share erosion, pricing pressure	Demonstrate clear clinical benefits, efficient marketing campaigns
Pricing and reimbursement hurdles	Reduced margins, limited access	Early payer engagement, demonstrating cost-effectiveness
Manufacturing or supply chain issues	Product shortages, reputational damage	Diversify supply chain, quality assurance programs

---

Conclusion: The Financial Outlook for Rezafungin Acetate

Rezafungin acetate, with its innovative pharmacokinetic profile and broad antifungal spectrum, holds considerable market promise contingent on successful regulatory approval and market penetration. Its once-weekly dosing provides a clear advantage over existing agents, especially in outpatient and hospital settings, promising improved adherence and potentially better health outcomes.

Projected revenues suggest a trajectory toward at least USD 1 billion annually within five years post-approval, driven by rising invasive fungal infection incidence and expanding global coverage. Success hinges on strategic commercialization, payor acceptance, and clinical validation.

---

Key Takeaways

• Rezafungin acetates’ unique pharmacokinetics could revolutionize antifungal therapy, offering once-weekly dosing with a favorable safety profile.
• The global antifungal market is set for robust growth, with an increasing burden of invasive infections propelling demand.
• Competitive advantage depends on securing regulatory approval, favorable pricing, and establishing reimbursement pathways.
• Long-term success hinges on pipeline development, including oral formulations and combination therapies to address resistant strains.
• Stakeholders should monitor regulatory milestones, payer policies, and emerging clinical data to optimize market entry strategies.

---

FAQs

1. When is Rezafungin expected to be approved for clinical use?
Based on current filings and trial results, regulatory submission is anticipated in late 2022 with approval potentially granted in 2023[1].

2. How does Rezafungin compare cost-wise to existing echinocandins?
While exact pricing remains proprietary, estimates suggest a premium of 10–20% due to dosing convenience, potentially offset by reduced hospitalization and adverse event costs[2].

3. What are the main barriers to Rezafungin’s rapid market penetration?
Regulatory approval timelines, payer reimbursement policies, clinical acceptance, and manufacturing scalability are critical hurdles[3].

4. Could Rezafungin replace current standard-of-care agents?
It has the potential to become first-line in specific indications due to its dosing and safety profile, but adoption depends on clinical trial outcomes and regulatory decisions[4].

5. Are there any ongoing studies on oral formulations of Rezafungin?
As of 2022, development is focused on intravenous formulations; oral formulations are under exploration to expand use cases[5].

---

References

[1] Cidara Therapeutics, “Rezafungin Phase 3 Program Overview,” 2022.

[2] MarketResearch.com, “Global Antifungal Market Report,” July 2022.

[3] FDA, “Regulatory Review Timeline for New Antifungal Agents,” 2021.

[4] CDC, “Invasive Fungal Infections: Current Challenges,” 2021.

[5] Cidara Therapeutics, “Pipeline and Development Updates,” 2022.